Allarity Therapeutics, Inc.
ALLR- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001860657
No open-market purchases or sales by Allarity Therapeutics, Inc. insiders were filed in the last 90 days; 20 institutions reported holding it in 13F filings for Q2 2026, worth $1.65M in total; no superinvestor holds it.
Q4 2024 vs. Q3 2024
How the institutions holding Allarity Therapeutics, Inc. changed between Q3 2024 and Q4 2024.
All holders in Q4 2024All holders in Q3 2024
| Measure | Q3 2024 | Q4 2024 | Change |
|---|---|---|---|
| Holders | 4 | 6 | +2 |
| Shares | 21.9K | 104.5K | +82.6K (+377.7%) |
| Value | $46.2K | $122.3K | +$76.1K (+164.9%) |
New holders (3)
Institutions that held Allarity Therapeutics, Inc. at the end of Q4 2024 but not at the end of Q3 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Stonepine Capital Management, LLC | 67,289 | $78.7K | 0.06% |
| Goldman Sachs Group Inc | 20,616 | $24.1K | 0.00% |
| Citigroup Inc | 12,294 | $14.4K | 0.00% |
Sold out (1)
Institutions that held Allarity Therapeutics, Inc. at the end of Q3 2024 and filed for Q4 2024 without it.
| Institution | Shares, Q3 2024 | Value, Q3 2024 |
|---|---|---|
| UBS Group AG | 18,452 | $38.9K |